Display options
Cite
Santantonio TA, Fasano M. Chronic hepatitis B: Advances in treatment. World J Hepatol. 2014;6(5):284-92doi: 10.4254/wjh.v6.i5.284.
Santantonio, T. A., & Fasano, M. (2014). Chronic hepatitis B: Advances in treatment. World journal of hepatology, 6(5), 284-92. https://doi.org/10.4254/wjh.v6.i5.284
Santantonio, Teresa Antonia, and Fasano, Massimo. "Chronic hepatitis B: Advances in treatment." World journal of hepatology vol. 6,5 (2014): 284-92. doi: https://doi.org/10.4254/wjh.v6.i5.284
Santantonio TA, Fasano M. Chronic hepatitis B: Advances in treatment. World J Hepatol. 2014 May 27;6(5):284-92. doi: 10.4254/wjh.v6.i5.284. PMID: 24868322; PMCID: PMC4033286.
Copy Download .nbib Format: NLM
Share it on

World J Hepatol. 2014 May 27;6(5):284-92. doi: 10.4254/wjh.v6.i5.284.

Chronic hepatitis B: Advances in treatment.

World journal of hepatology

Teresa Antonia Santantonio, Massimo Fasano

Affiliations

  1. Teresa Antonia Santantonio, Massimo Fasano, Department of Clinical and Experimental Medicine, University of Foggia, 71100 Foggia, Italy.

PMID: 24868322 PMCID: PMC4033286 DOI: 10.4254/wjh.v6.i5.284

Abstract

Treatment of chronic hepatitis B (CHB) has markedly improved in the last 15 years due to the availability of direct antivirals which greatly increase therapeutic options. Currently, there are two classes of agents licensed for CHB treatment: standard or pegylated interferon alpha (IFN or Peg-IFN) and five nucleoside/nucleotide analogues (NAs). Long-term treatment with NAs is the treatment option most often used in the majority of CHB patients. Entecavir and tenofovir, the most potent NAs with high barrier to resistance, are recommended as first-line monotherapy by all major treatment guidelines and can lead to long-lasting virological suppression, resulting in histological improvement or reversal of advanced fibrosis and reduction in disease progression and liver-related complications. In this review, we focus on current treatment strategies of chronic hepatitis B and discuss the most recent efficacy and safety data from clinical trials and real life clinical practice. Recent findings of response-guided approaches are also discussed.

Keywords: Antiviral resistance; Antiviral therapy; Chronic hepatitis; Nucleos(t)ide analogues; Peg-interferon

References

  1. J Hepatol. 2013 Dec;59(6):1153-9 - PubMed
  2. Hepatology. 2011 Aug;54(2):443-51 - PubMed
  3. Hepatology. 2009 Sep;50(3):661-2 - PubMed
  4. Antivir Ther. 2009;14(8):1165-74 - PubMed
  5. N Engl J Med. 2004 Sep 16;351(12):1206-17 - PubMed
  6. Hepatol Int. 2013 Jun;7(2):429-36 - PubMed
  7. J Hepatol. 2012 May;56(5):1006-1011 - PubMed
  8. Antivir Ther. 2011;16(5):629-37 - PubMed
  9. Hepatology. 2010 Aug;52(2):454-61 - PubMed
  10. Am J Gastroenterol. 2010 Aug;105(8):1762-9 - PubMed
  11. Hepatology. 2013 Sep;58(3):872-80 - PubMed
  12. Gastroenterology. 2010 Aug;139(2):491-8 - PubMed
  13. Hepatology. 2012 Jul;56(1):67-75 - PubMed
  14. Antiviral Res. 2012 Feb;93(2):297-300 - PubMed
  15. Hepatology. 2009 Dec;50(6):2001-6 - PubMed
  16. J Gastroenterol Hepatol. 2011 Apr;26(4):628-38 - PubMed
  17. Aliment Pharmacol Ther. 2005 May 1;21(9):1163-71 - PubMed
  18. Hepatology. 2011 Nov;54(5):1591-9 - PubMed
  19. Eur J Gastroenterol Hepatol. 2012 May;24(5):535-42 - PubMed
  20. Gastroenterology. 2008 Aug;135(2):459-67 - PubMed
  21. Hepatology. 2013 Mar;57(3):890-6 - PubMed
  22. Lancet. 2005 Jan 8-14;365(9454):123-9 - PubMed
  23. Hepatology. 2010 Feb;51(2):422-30 - PubMed
  24. Hepatology. 2011 Jan;53(1):62-72 - PubMed
  25. J Viral Hepat. 2004 Mar;11(2):97-107 - PubMed
  26. Lancet. 2013 Feb 9;381(9865):468-75 - PubMed
  27. N Engl J Med. 2008 Dec 4;359(23):2442-55 - PubMed
  28. J Hepatol. 2008 Oct;49(4):652-7 - PubMed
  29. Gastroenterology. 2009 Dec;137(6):2002-9 - PubMed
  30. Hepatology. 2003 Jun;37(6):1309-19 - PubMed
  31. Hepatology. 2014 Feb;59(2):434-42 - PubMed
  32. Hepatology. 2009 May;49(5):1503-14 - PubMed
  33. N Engl J Med. 2005 Jun 30;352(26):2682-95 - PubMed
  34. J Hepatol. 2012;56 Suppl 1:S112-22 - PubMed
  35. J Hepatol. 2010 Feb;52(2):176-82 - PubMed
  36. Gut. 2013 May;62(5):760-5 - PubMed
  37. Gastroenterology. 2011 Oct;141(4):1240-8, 1248.e1-2 - PubMed
  38. Gastroenterology. 2012 Mar;142(3):513-520.e1 - PubMed
  39. Gut. 2013 Feb;62(2):290-8 - PubMed
  40. J Hepatol. 2012 Jul;57(1):167-85 - PubMed
  41. Hepatol Int. 2008 Sep;2(3):263-83 - PubMed

Publication Types